Twinbeech Capital LP Purchases 1,743,849 Shares of Pfizer Inc. (NYSE:PFE)

Twinbeech Capital LP increased its position in Pfizer Inc. (NYSE:PFE - Free Report) by 303.4% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,318,613 shares of the biopharmaceutical company's stock after purchasing an additional 1,743,849 shares during the period. Pfizer accounts for 1.1% of Twinbeech Capital LP's portfolio, making the stock its 20th biggest position. Twinbeech Capital LP's holdings in Pfizer were worth $61,513,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in the company. Tallon Kerry Patrick purchased a new stake in shares of Pfizer during the fourth quarter valued at approximately $509,000. Merit Financial Group LLC increased its holdings in shares of Pfizer by 60.8% in the 4th quarter. Merit Financial Group LLC now owns 127,967 shares of the biopharmaceutical company's stock worth $3,395,000 after purchasing an additional 48,397 shares in the last quarter. Sax Wealth Advisors LLC raised its stake in shares of Pfizer by 17.4% in the fourth quarter. Sax Wealth Advisors LLC now owns 10,995 shares of the biopharmaceutical company's stock worth $292,000 after purchasing an additional 1,630 shares during the last quarter. Lake Street Private Wealth LLC lifted its holdings in shares of Pfizer by 8.3% during the fourth quarter. Lake Street Private Wealth LLC now owns 10,096 shares of the biopharmaceutical company's stock valued at $268,000 after purchasing an additional 776 shares in the last quarter. Finally, Ameritas Advisory Services LLC boosted its position in shares of Pfizer by 3.6% during the fourth quarter. Ameritas Advisory Services LLC now owns 75,983 shares of the biopharmaceutical company's stock valued at $2,016,000 after buying an additional 2,633 shares during the last quarter. Institutional investors own 68.36% of the company's stock.

Analysts Set New Price Targets

Several equities analysts have issued reports on the stock. Hsbc Global Res upgraded shares of Pfizer to a "strong-buy" rating in a research note on Monday, March 10th. UBS Group increased their price objective on shares of Pfizer from $24.00 to $25.00 and gave the company a "neutral" rating in a research report on Wednesday, April 30th. Cantor Fitzgerald initiated coverage on shares of Pfizer in a research note on Tuesday, April 22nd. They set a "neutral" rating and a $24.00 target price for the company. Citigroup reissued a "neutral" rating on shares of Pfizer in a report on Thursday, March 27th. Finally, The Goldman Sachs Group reiterated a "neutral" rating and set a $25.00 price objective (down previously from $32.00) on shares of Pfizer in a research report on Tuesday, April 8th. One analyst has rated the stock with a sell rating, eight have given a hold rating, four have issued a buy rating and three have assigned a strong buy rating to the company. According to MarketBeat, Pfizer currently has a consensus rating of "Moderate Buy" and an average target price of $29.17.

Pfizer Price Performance

Shares of PFE traded up $0.51 during mid-day trading on Tuesday, reaching $23.51. The stock had a trading volume of 56,982,321 shares, compared to its average volume of 41,026,680. The business has a fifty day moving average of $23.56 and a 200 day moving average of $25.27. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The firm has a market cap of $133.66 billion, a price-to-earnings ratio of 16.67, a PEG ratio of 0.64 and a beta of 0.58. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $31.54.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.67 by $0.25. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The business had revenue of $13.72 billion during the quarter, compared to analyst estimates of $14.43 billion. During the same quarter in the prior year, the business posted $0.82 EPS. Pfizer's revenue for the quarter was down 7.8% compared to the same quarter last year. Equities analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 13th. Stockholders of record on Friday, May 9th will be given a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 7.32%. The ex-dividend date of this dividend is Friday, May 9th. Pfizer's payout ratio is currently 124.64%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.